Trial Profile
A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2016
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Atopic dermatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors AstraZeneca; Takeda Pharmaceuticals International GmbH
- 15 Aug 2014 New trial record
- 04 Jun 2009